# Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

Source: https://onco.cc/trials/nct07155226/  
OnCo record `nct07155226` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AZD3632 in acute lymphoblastic leukaemia, acute myeloid leukaemia and myelodysplastic syndromes / neoplasms, run by AstraZeneca, now recruiting.

## Summary

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression is a phase 1/2 interventional study registered as NCT07155226 by AstraZeneca, with 84 participants planned, started 2026-01-09 and due to reach its primary completion in 2029-02-15. Interventions recorded: AZD3632 and Posaconazole.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07155226
- Phase: 1/2
- Setting: A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Sponsor: AstraZeneca
- Enrolled: 84

## Sources

- ClinicalTrials.gov NCT07155226: https://clinicaltrials.gov/study/NCT07155226

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct07155226.json